Emerging Therapies Through Kidney-on-Chip Platforms for Regenerative Medicine

Abstract

Over the last decade, kidney-on-chip (KoC) technology has rapidly evolved, offering unique opportunities for the development of regenerative therapies. By mimicking the complex microarchitecture and physiological functions of renal tissue, KoC platforms provide innovative avenues to investigate disease mechanisms, test therapeutic agents, and enable personalized approaches in nephrology. This review synthesizes the current landscape of KoC systems, highlighting their clinical relevance in addressing the global burden of kidney diseases and their potential to advance regenerative medicine through translational research and emerging therapies.

Introduction

Chronic kidney disease (CKD) and acute kidney injury (AKI) represent significant healthcare challenges, with limited therapeutic options and high morbidity and mortality rates. Traditional in vitro and in vivo models have limitations in recapitulating human renal physiology and disease mechanisms. The advent of kidney-on-chip platforms, which integrate microfluidics, 3D cell cultures, and biomimetic engineering, has revolutionized preclinical nephrology research. These systems create physiologically relevant microenvironments, enabling more accurate disease modeling, drug screening, and regenerative therapy development. This article reviews the role of KoC technologies in regenerative medicine, focusing on their applications, mechanisms, and future potential for clinicians and researchers.

Epidemiology / Disease Burden

Kidney diseases account for substantial global morbidity and mortality. CKD affects approximately 10% of the adult population worldwide, with an estimated 850 million individuals living with some form of renal impairment. AKI remains a common complication in hospitalized patients, particularly in critical care settings, and is associated with increased risk of progression to CKD, cardiovascular events, and death. The socioeconomic impact is profound, straining healthcare systems and highlighting the urgent need for novel, effective therapies and improved disease models to bridge gaps in treatment and prognosis.

Pathophysiology

Renal diseases are characterized by complex interactions between glomerular, tubular, and vascular components. CKD often arises from chronic insults such as hypertension, diabetes, or glomerulonephritis, leading to progressive fibrosis, tubular atrophy, and capillary rarefaction. In AKI, rapid loss of renal function is commonly triggered by ischemia, nephrotoxins, or sepsis, leading to tubular epithelial injury, inflammation, and microvascular dysfunction. Pathophysiological heterogeneity and the interplay with systemic factors underscore the necessity for advanced in vitro models that recapitulate these multifaceted processes for research and therapeutic development.

Risk Factors

Major risk factors for kidney disease include advanced age, diabetes mellitus, hypertension, family history of renal disorders, obesity, cardiovascular disease, and exposure to nephrotoxic agents. Socioeconomic determinants and genetic predispositions further modulate individual susceptibility and disease progression. Identification and stratification of these risk factors are crucial for targeted prevention, early intervention, and personalized therapy selection, which can be facilitated by advanced disease modeling platforms such as KoC systems.

Clinical Features

Patients with kidney disease present with diverse clinical manifestations, ranging from asymptomatic laboratory abnormalities to overt symptoms such as edema, hypertension, hematuria, and uremic syndrome in advanced stages. AKI often manifests acutely with oliguria, fluid overload, electrolyte disturbances, and rapid biochemical derangements. Early recognition and characterization of clinical features are essential for timely diagnosis, management, and prognostication, emphasizing the need for effective preclinical tools to model and study these clinical entities.

Diagnosis

Diagnosis of renal diseases relies on a combination of clinical assessment, laboratory evaluation (serum creatinine, estimated GFR, urinary biomarkers), and imaging studies. Renal biopsy may be required for definitive diagnosis in select cases. Despite advancements, current diagnostic approaches have limitations in sensitivity, specificity, and predictive accuracy, particularly in early or atypical presentations. Kidney-on-chip platforms offer the potential to develop and validate novel biomarkers, enhance mechanistic understanding, and improve diagnostic precision through patient-specific modeling.

Treatment & Management

Management of CKD and AKI is primarily supportive, focusing on risk factor modification, blood pressure and glycemic control, avoidance of nephrotoxins, and mitigation of complications such as anemia, mineral bone disorder, and cardiovascular disease. Renal replacement therapies—hemodialysis, peritoneal dialysis, and transplantation—remain the cornerstone for end-stage disease. However, the lack of disease-modifying therapies and organ shortages for transplantation underline the urgent demand for regenerative approaches and novel therapeutics.

Recent Advances / Emerging Therapies

Kidney-on-chip technology has emerged as a transformative tool in nephrology research. These microfluidic devices recapitulate key renal functions, including glomerular filtration, tubular reabsorption, and secretion, by combining human-derived renal cells with biomimetic scaffolds and controlled fluidic environments. KoC systems enable high-throughput drug screening, toxicity testing, and disease modeling, overcoming species differences and static culture limitations seen in traditional models. Recent advances include the integration of patient-specific induced pluripotent stem cells (iPSCs) into KoC platforms to generate personalized renal microtissues, facilitating precision medicine and the evaluation of regenerative therapies such as stem cell-derived organoids, gene editing, and extracellular vesicle-based interventions. Furthermore, KoC platforms are being used to assess the efficacy and safety of novel antifibrotic agents, immunomodulators, and regenerative molecules in preclinical settings. The ability to model complex interactions between renal parenchymal, endothelial, and immune cells in a tunable, physiologically relevant context opens new avenues for understanding disease mechanisms and optimizing therapeutic strategies. These platforms also support the study of kidney regeneration and repair following injury, providing insights into cellular crosstalk, extracellular matrix remodeling, and endogenous repair pathways.

Guideline Recommendations

Current international guidelines, such as those from KDIGO, emphasize the importance of early diagnosis, risk factor modification, and evidence-based management of CKD and AKI. While regenerative therapies and KoC platforms are not yet standard of care, emerging consensus highlights their potential to enhance preclinical research, accelerate drug development, and inform clinical trial design. Ongoing multicenter efforts advocate for the integration of KoC-derived data into translational pipelines, with the goal of bridging preclinical findings to clinical applications and ultimately improving patient outcomes.

Conclusion

Kidney-on-chip platforms are at the forefront of innovation in nephrology, offering unprecedented opportunities to model human renal physiology, elucidate disease mechanisms, and develop regenerative therapies. Their integration into research and therapeutic pipelines promises to advance precision medicine, optimize drug development, and address the global burden of kidney diseases. Continued interdisciplinary collaboration and investment in KoC technologies will be critical for translating these advances into meaningful clinical benefits for patients with renal disorders.